PPM1D and triple-negative breast carcinoma: In our study, triple-negative breast cancer patients with different senescence subtypes had different drug sensitivities, and small molecule drugs such as the VEGFR inhibitor AMG.706, PPM1D inhibitor CCT007093, and GSK-3α/β inhibitor CHR.99021 were more effective in the TNBCSASP1 subtype.